Bank of America maintained Cardinal Health CAH with a Buy rating and lowered the price target from $49.00 to $47.00.
Bank of America analyst Robert M. Willoughby wrote, "CAH will lose its supply relationship with Walgreens, effective September 1, as indicated by the retailer's new 10-year agreement announced this morning. The contract was worth approximately $28 billion in annual revenues (~21% of CAH's FY12 sales), but at margins considerably below its corporate average (~9% of EBITDA). We are lowering our FY14 EPS estimate to $3.50 (from $3.95) on the lost business. Our P.O. moves to $47 (from $49), reflecting modestly improved multiples on our revised earnings expectations for the stronger implied dividend yield."
Cardinal Health closed at $42.95 on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in